Ex-ImClone CEO Lynch joins Third Rock; TetraLogic raises venture take to $43M; regulators want new Ph3 for Huntington's drug;

@FierceBiotech:  Sanofi's Zerhouni drops biotech model in favor of "open innovation." Story | Follow @FierceBiotech

@JohnCFierce: Panel at BIO June 29 includes execs from AstraZeneca, Acorda, HGS and Sanofi. Follow @JohnCFierce

> Former ImClone CEO Dan Lynch has joined up with Third Rock as an entrepreneur-in-residence. Third Rock, an active venture player, has spawned a string of biotech start-ups in recent years. And it often turns to its entrepreneurs to fill top slots. Release

> TetraLogic Pharmaceuticals has closed a $6 million investment with new investor Nextech Invest. Combined with the $37 million Series C closed during 2010, TetraLogic has raised $43 million in the past year. Release

> Denmark's Neurosearch says that it will need to mount a new Phase III study if it expects to win over regulators in Europe for its Huntington's drug Huntexil. Story

> The once-promising UK biotech Antisoma is now down to 0 full time employees, reports Pharma Times. The board says it's studying its "options." Story

> Ampio Pharmaceuticals is touting late-stage results for its new drug for premature ejaculation. Ampio says it is now in a position to file for approval of Zertane in Europe. Report

Pharma News

@FiercePharma: Facebook: No more 'no comment' for pharma. News | Follow @FiercePharma

> Shire may look to bulk up with $2B Cubist deal. Report

> NICE approves MabThera for lymphoma maintenance. Story

> AZ to co-promote Amgen bone drug in Japan. News

> Lilly launches new venture to market Xigris. Item

> Prompted by Tamiflu probe, Canada mulls conflicts disclosure. Piece

Biotech Research News

> Scientists find better mouse model for major depressive disorder. News 

> Scientists use stem cells to cook up a batch of astrocytes, the brain's workhorses. Item 

> Brain has protective proteins that make it stronger after attack. Article 

> Heart failure progression is in the PINK1 gene. Story

>  WHO decides not to decide on remaining smallpox stockpiles. Item 

Manufacturing News

> QbD process steps studied in regulatory pilot. Report

> Thieves target generics in Pfizer trailer heist. News

> Issa wants FDA speed on J&J rehab. Item

> FTC asked to consider drug supply in pharma rulings. Story

> Show product flow in plant design plans. Report

And Finally...Mummies found along the Nile point to age-old irrigation techniques as a prime culprit behind the plague of schistosomiasis which infects an estimated 200 million people. Report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.